Reversible azoospermia induced by an androgen‐progestin combination regimen in Indonesian men
Author:
Open Access
- 1 August 1991
- journal article
- clinical trial
- Published by Wiley in International Journal of Andrology
- Vol. 14 (4) , 248-256
Abstract
Summary: The suppression of spermatogenesis by a combination of depot medroxyprogester‐one acetate (DMPA) and testosterone enanthate (TE) was studied in Indonesian men. Twenty healthy, fertile volunteers were allocated randomly to either of two treatments each consisting of four intramuscular injections at monthly intervals. Group I (n=10 men) received 100 mg DMPA plus 100 mg TE monthly while group II (n = 10 men) received 200 mg DMPA plus 250 mg TE monthly. Sperm concentration was suppressed markedly, with all men attaining azoospermia between the third and fourth month after the start of treatment. There was no significant difference in the suppression of spermatogenesis between the two dos age regimens. The median time to reaching azoospermia was 2.5 months from the onset of injections and the median time to recovery of sperm in the ejaculate was 2.0 months after cessation of treatment. Both steroid regimens were equally effective in suppressing LH, FSH and testosterone levels. Testosterone levels returned to baseline by the fourth post‐treatment month while LH and FSH demonstrated significant rebound above baseline levels from 3 to 5 months after cessation of treatment. No serious clinical side effects were observed. Weight gain and increases in libido were reported during treatment by most volunteers. A transient decrease in libido was noted in 5/20 (25%) men between 1–2 months after cessation of injections, presumably due to the prolonged effects of DMPA relative to TE. These results indicate that uniform induction of reversible azoospermia with minimal side effects can be achieved in a non‐Causasian population. This study therefore supports the feasibility of an effective and reversible hormonal male‐contraceptive in some populations even if this requires the consistent induction of azoospermia. The explanation for the higher frequency of azoospermia induced in Indonesian compared with Caucasian men remains to be clarified and is strategically critical to the future development of male contraception.Keywords
This publication has 23 references indexed in Scilit:
- Elevated Serum Lipids in Hypogonadal Men with and without HyperprolactinemiaAnnals of Internal Medicine, 1989
- Combination of 19-nortestosterone-hexyloxyphenylpropionate (Anadur) and depot-medroxyprogesterone-acetate (Clinovir) for male contraceptionFertility and Sterility, 1989
- Return of ovulation following a single injection of depo-medroxyprogesterone acetate: A pharmacokinetic and pharmacodynamic studyContraception, 1984
- Plasma levels and pharmacokinetics of ethynyl estrogens in various populationsContraception, 1980
- Plasma levels and pharmacokinetics of ethynyl estrogens in various populationsContraception, 1980
- Study of medroxyprogesterone acetate and testosterone enanthate as a male contraceptiveContraception, 1977
- The effect of monthly depot medroxyprogesterone acetate and testosterone on human spermatogenesis. II. High initial doseContraception, 1977
- The effect of monthly depot medroxyprogesterone acetate and testosterone on human spermatogenesis I. Uniform dosage levelsContraception, 1977
- Attainment and maintenance of azoospermia with combined monthly injections of depot medroxyprogesterone acetate and testosterone enanthateContraception, 1977
- Inhibition of spermatogenesis in men with monthly injections of medroxyprogesterone acetate and testosterone enanthateContraception, 1977